Crossmark

Efficacy, safety and exploratory analysis of neoadjuvant tislelizumab (a PD-1 inhibitor) plus nab-paclitaxel followed by epirubicin/cyclophosphamide for triple-negative breast cancer: a phase 2 TREND trial

Crossref DOI link: https://doi.org/10.1038/s41392-025-02254-3

Published Online: 2025-05-26

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhang, Qiang

Wang, Mozhi

Li, Yumeng

Zhang, Hengjun

Wang, Yusong

Chen, Xiuyun

Yao, Litong

Cui, Mingke

Dong, Haoran

Li, Xiang

Liu, Jian

Zhu, Bo https://orcid.org/0000-0003-0224-8512
Xu, Yingying https://orcid.org/0000-0002-9420-1123
Funding

Funding for this research was provided by:

Natural Science Foundation of Liaoning Province (2022-YGJC-68, 2023-BS-105)
License Information

Text and Data Mining valid from 2025-05-26

Version of Record valid from 2025-05-26
More Information

Article History

Received: 25 November 2024

Revised: 13 April 2025

Accepted: 28 April 2025

First Online: 26 May 2025

Competing interests

: The authors declare no competing interests.

Document is current

Any future updates will be listed below